Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
Aclaris Therapeutics (NASDAQ: ACRS) has announced the formation of a new Scientific Advisory Board (SAB) focused on pulmonology expertise. The initial board includes two distinguished members: Dr. Marianne Mann, a pulmonologist with over 30 years of experience in regulatory science and former FDA Deputy Director, and Dr. Zuzana Diamant, a renowned pulmonologist and clinical pharmacologist.
Dr. Mann brings extensive experience in clinical trial design and regulatory strategy from her roles at the FDA and NIH. Dr. Diamant, a guest professor at KU Leuven and past-chair of multiple respiratory medicine organizations, has co-authored over 200 peer-reviewed publications and brings expertise in drug development and clinical studies for respiratory diseases.
The SAB will guide Aclaris's development programs for immuno-inflammatory diseases, leveraging the members' combined expertise in respiratory medicine, clinical pharmacology, and immunology.
Aclaris Therapeutics (NASDAQ: ACRS) ha annunciato la formazione di un nuovo Comitato Consultivo Scientifico (SAB) specializzato in pneumologia. Il comitato iniziale include due membri di spicco: Dr. Marianne Mann, pneumologo con oltre 30 anni di esperienza nella scienza regolatoria e già Vice Direttore della FDA, e Dr. Zuzana Diamant, una pneumologa e farmacologa clinica rinomata.
Il Dr. Mann porta un'ampia esperienza nella progettazione di trial clinici e strategie regolatorie derivanti dai suoi ruoli presso la FDA e il NIH. Il Dr. Diamant, professore ospite presso la KU Leuven e ex presidente di diverse organizzazioni di medicina respiratoria, ha co-autore oltre 200 pubblicazioni sottoposte a peer review e vanta una competenza nello sviluppo di farmaci e negli studi clinici per malattie respiratorie.
Il SAB guiderà i programmi di sviluppo di Aclaris per le malattie immuno-infiammatorie, sfruttando le competenze congiunte dei membri in medicina respiratoria, farmacologia clinica e immunologia.
Aclaris Therapeutics (NASDAQ: ACRS) ha anunciado la formación de un nuevo Comité Asesor Científico (SAB) centrado en la experiencia en neumología. El comité inicial incluye a dos miembros distinguidos: Dr. Marianne Mann, neumóloga con más de 30 años de experiencia en ciencia regulatoria y ex Subdirectora de la FDA, y Dr. Zuzana Diamant, una renombrada neumóloga y farmacóloga clínica.
La Dra. Mann aporta una amplia experiencia en el diseño de ensayos clínicos y estrategias regulatorias adquiridas en sus roles en la FDA y el NIH. La Dra. Diamant, profesora visitante en KU Leuven y ex presidenta de múltiples organizaciones de medicina respiratoria, ha coautorado más de 200 publicaciones revisadas por pares y aporta experiencia en desarrollo de medicamentos y estudios clínicos para enfermedades respiratorias.
El SAB guiará los programas de desarrollo de Aclaris para enfermedades inmunoinflamatorias, aprovechando la experiencia combinada de sus miembros en medicina respiratoria, farmacología clínica e inmunología.
Aclaris Therapeutics (NASDAQ: ACRS)는 호흡기 전문성을 중점으로 두고 새로운 과학 자문 위원회(SAB)를 구성했다고 발표했습니다. 초대 위원회에는 두 명의 저명한 멤버가 포함되어 있습니다: Dr. Marianne Mann, 규제 과학에서 30년 이상의 경험을 가진 호흡기 전문가이자 전 FDA 부국장, 그리고 Dr. Zuzana Diamant, 유명한 호흡기 전문가이자 임상 약리학자입니다.
Dr. Mann은 FDA와 NIH에서의 역할을 통해 임상 시험 디자인 및 규제 전략에서 폭넓은 경험을 제공합니다. Dr. Diamant는 KU 루벤 대학의 초빙 교수이자 여러 호흡기 의학 단체의 전 회장으로, 200편 이상의 동료 리뷰 논문을 공동 저술한 경험이 있으며, 호흡기 질환에 대한 약물 개발 및 임상 연구에서 전문성을 보유하고 있습니다.
SAB는 호흡기 의학, 임상 약리학 및 면역학에 대한 회원들의 결합된 전문성을 활용하여 면역 염증 질환에 대한 Aclaris의 개발 프로그램을 안내할 것입니다.
Aclaris Therapeutics (NASDAQ: ACRS) a annoncé la formation d'un nouveau Conseil Consultatif Scientifique (SAB) axé sur l'expertise en pneumologie. Le conseil initial comprend deux membres distingués : Dr. Marianne Mann, pneumologue avec plus de 30 ans d'expérience en science réglementaire et ancienne directrice adjointe de la FDA, et Dr. Zuzana Diamant, pneumologue de renom et pharmacologue clinique.
Le Dr. Mann apporte une vaste expérience en matière de conception d'essais cliniques et de stratégie réglementaire grâce à ses rôles à la FDA et au NIH. Le Dr. Diamant, professeur invité à la KU Leuven et ancienne présidente de plusieurs organisations de médecine respiratoire, a coécrit plus de 200 publications évaluées par des pairs et apporte son expertise en développement de médicaments et en études cliniques pour les maladies respiratoires.
Le SAB guidera les programmes de développement d'Aclaris pour les maladies immuno-inflammatoires, en s'appuyant sur l'expertise combinée de ses membres en médecine respiratoire, pharmacologie clinique et immunologie.
Aclaris Therapeutics (NASDAQ: ACRS) hat die Bildung eines neuen Wissenschaftlichen Beirats (SAB) bekannt gegeben, der sich auf Expertise in der Pulmonologie konzentriert. Der anfängliche Beirat umfasst zwei angesehene Mitglieder: Dr. Marianne Mann, eine Pneumologin mit über 30 Jahren Erfahrung in der regulatorischen Wissenschaft und ehemalige stellvertretende Direktorin der FDA, sowie Dr. Zuzana Diamant, eine renommierte Pneumologin und klinische Pharmakologin.
Dr. Mann bringt umfangreiche Erfahrung in der Gestaltung klinischer Studien und regulatorischen Strategien aus ihren Rollen bei der FDA und NIH mit. Dr. Diamant, Gastprofessorin an der KU Leuven und ehemalige Vorsitzende mehrerer Organisationen für Atemwegserkrankungen, hat über 200 begutachtete Publikationen mitverfasst und bringt Expertise in der Arzneimittelentwicklung und klinischen Studien für Atemwegserkrankungen mit.
Der SAB wird Aclaris bei den Entwicklungsprogrammen für immunentzündliche Erkrankungen beraten und dabei die kombinierte Expertise der Mitglieder in der Atemwegsmedizin, klinischen Pharmakologie und Immunologie nutzen.
- Formation of specialized Scientific Advisory Board with expertise in respiratory medicine and drug development
- Addition of former FDA Deputy Director with regulatory expertise
- Integration of experienced clinical researcher with over 200 peer-reviewed publications
- None.
WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board (SAB), which initially includes experts in the field of pulmonology. These include Marianne Mann, M.D., and Zuzana Diamant, M.D., Ph.D. leading experts in respiratory medicine, clinical pharmacology, and immunology.
"We are delighted to welcome these distinguished scientists and clinicians to our Scientific Advisory Board," said Dr. Neal Walker, Interim CEO and Chair of the Board of Directors of Aclaris Therapeutics. "Their expertise in respiratory medicine and drug development will be important in guiding our development programs as we work to advance novel therapeutics for patients with immuno-inflammatory diseases. Each initial member brings unique and complementary experience spanning regulatory science, clinical development, and translational research that will help guide our development programs."
The members of the Scientific Advisory Board are:
Marianne Mann, M.D.
Dr. Mann is an accomplished pulmonologist and drug development expert with over three decades of experience in regulatory science, clinical research and clinical care. She previously served in various roles at the FDA, including Deputy Director of the Division of Pulmonary and Allergy Drug Products at the FDA's Center for Drug Evaluation and Research, where she played a pivotal role in evaluating clinical protocols for respiratory and allergic conditions. In addition, Dr. Mann also previously served as the Branch Chief, Respiratory Disease Branch, for the Division of Microbiology and Infectious Diseases at the National Institutes of Health, where she oversaw research in respiratory diseases. Dr. Mann has extensive experience in clinical trial design, drug safety assessment, and regulatory strategy.
Zuzana Diamant, M.D., Ph.D.
Dr. Diamant is a distinguished pulmonologist and clinical pharmacologist who serves as a guest professor at the Department of Microbiology Immunology & Transplantation at KU Leuven, Belgium and past-guest professor at the Department of Respiratory Medicine at Skane Hospital, Lund, Sweden. She is past-chair of the Asthma Section at European Academy of Allergy and Clinical Immunology and past-chair of the Asthma Expert Panel at European Forum for Research and Education in Allergy and has led several international task forces and educational projects on chronic inflammatory respiratory diseases. She brings extensive expertise in drug development and clinical studies in asthma, chronic obstructive pulmonary disease, and allergy research. Dr. Diamant has co-authored over 200 peer-reviewed publications and is a Fellow of the European Respiratory Society (FERS). Her expertise in clinical asthma models, biomarkers, and targeted drug interventions will be instrumental in guiding our development programs.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
FAQ
Who are the initial members of ACRS's new Scientific Advisory Board?
What is the purpose of ACRS's new Scientific Advisory Board?
What experience does Dr. Marianne Mann bring to ACRS's Scientific Advisory Board?
What are Dr. Zuzana Diamant's credentials on ACRS's new SAB?
